Publisher Correction: Top 20 translational researchers of 2020
Published in Nature Biotechnology
Publisher Correction: Top 20 translational researchers of 2020
Single-cell immunology of SARS-CoV-2 infection
Published in Nature Biotechnology
This Review provides an overview of existing studies using single-cell technologies to provide insights over the immune responses and molecular mechanisms at work in COVID-19.
Off-the-shelf, gene-edited CAR-T cells forge ahead, despite safety scare
Published in Nature Biotechnology
Race to the clinic reignites for an off-the-shelf alternative to autologous CAR-T cell therapy, even as concerns over chromosomal abnormalities linger.
GABA-enriched tomato is first CRISPR-edited food to enter market
Published in Nature Biotechnology
Sanatech Seed’s Sicilian Rouge CRISPR-edited ‘health-promoting’ tomatoes reach consumers and may open the market to more genome-edited fruit, vegetables and even fish.
The PROTAC gold rush
Published in Nature Biotechnology
Investment in small-molecule protein degraders is surging, but their drawbacks, limitations and risks are becoming clear.
T-cell vaccines could top up immunity to COVID, as variants loom large
Published in Nature Biotechnology
Peptide jabs targeting T cells could be especially useful for people with compromised immune systems, as backups for spike-based vaccines, or against Omicron and other emerging variants.
Nanotechnology offers alternative ways to fight COVID-19 pandemic with antivirals
Published in Nature Biotechnology
A new wave of funding focuses on antiviral nanomaterials as pandemic countermeasures.
Improving scientific communication with service, education and career development
Published in Nature Biotechnology
A trainee-run group that provides editing and schema design services not only enhances scientific communication for clients, but also trains its members in communication, writing and other transferrable skills.
Drug hunters uncloak the non-coding ‘hidden’ genome
Published in Nature Biotechnology
Scientists are using new tools to mine the non-coding part of the genome, known as ‘dark matter’, to uncover disease-linked changes in promoters, silencers and enhancers for target discovery.
Patent landscape of brain–machine interface technology
Published in Nature Biotechnology
A study of the brain–machine interface patent landscape suggests that the technology is in its early stages of development, but patent applications have been increasing exponentially in recent years.
